ClinicalTrials.gg
Active, not recruitingNCT02945566STAR-TRECUpdated Jun 29, 2026

Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?

A Phase 2/3 interventional study of Standard TME surgery and Long course concurrent chemoradiation with capecitabine and radiotherapy in Adenocarcinoma of the Rectum, sponsored by University of Birmingham. Active, not recruiting at 5 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by University of Birmingham · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.

Planned enrollment
15th of 45
380 · median 156
Started
2017
with 4 others
Phase 2/3
Only one
of the 56
Primary completion
2027-08
later than 12 of 19 live
Registered
30th of 56
by date

Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 15th largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2017, is the only one in phase 2/3, reaches primary completion later than 12 of the 19 other live ones, and was the 30th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Rectal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

Bowel cancer is the second most common tumour with 41 000 new cases diagnosed annually in the UK, 447 000 across Europe and 1.36 million worldwide; of which one third are located in the rectum. Standard primary radical Total Mesorectal Excision (TME) surgery is an oncologically effective treatment for early stage rectal cancer. However, resection of a low rectal tumour requires a permanent stoma in approximately 10% of cases while many more patients have a temporary stoma, some of which are not reversed. Radical surgery, which evolved to treat locally advanced, symptomatic tumours, may not be the optimal method of treatment for early screen-detected tumours and an organ preserving strategy may generate significantly less morbidity without substantially compromising oncological outcomes.

STAR-TREC is a rolling phase II/III study. Phase II aimed to assess the feasibility of a large, multi-centre randomised trial comparing radical surgery versus two contrasting organ saving treatments followed by selective transanal microsurgery. Phase III will evaluate two contrasting organ preservation strategies in terms of organ preservation rates, toxicity (clinician and patient-reported) and Health-Related Quality of Life (HRQoL).

Read the detailed description

The Phase II component of STAR-TREC (now completed) was a randomised, three arm (1:1:1) study using the following arms:

  1. Standard TME surgery (control)
  2. Organ saving treatments using:

    1. Long course concurrent chemoradiation:

      • Capecitabine: 825 mg/m² orally, b.d., on radiotherapy days
      • Radiotherapy: A dose of 50 Gy applied to the primary tumour and surrounding mesorectum in 25 fractions of 2 Gy, 5 days a week.
    2. Short course radiotherapy:

      • A dose of 25 Gy applied to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.

The phase III component of STAR_TREC is now open and has a partially randomised patient preference design where patients choose between organ saving treatment or standard surgery.

Those who prefer organ preservation will undergo randomisation 1:1 between:

  1. Long course concurrent chemoradiation (as described above)
  2. Short course radiotherapy (as described above)

Those who prefer standard surgery or have no preference, will undergo standard TME surgery without neoadjuvant radiotherapy treatment.

For organ-preserving strategies in phase II and III, clinical response to radiotherapy determines the next treatment step. Radiotherapy response is evaluated using clinical exam, endoscopy and MRI. The first assessment at 11-13 weeks (from radiotherapy start) using composite clinical, endoscopic and MRI based assessment will identify a minority of non-responders who should convert to TME surgery. Patients demonstrating a satisfactory radiotherapy response at 11-13 weeks will be reassessed by endoscopy at 16-20 weeks. Re-evaluation at 16-20 weeks determines if the STAR-TREC criteria for complete response (CR) are met. Patients who achieve CR may progress directly to active surveillance. Those who do not fulfil the criteria for CR will progress to excision biopsy with transanal endoscopic microsurgery (TEM).

The phase II component of the study aimed to evaluate the feasibility of accelerating patient recruitment from 2 per month, as attained in the previous TREC study, to 6 per month internationally over a two-year period.

The STAR-TREC phase III study will evaluate whether a CRT or SCRT organ preservation strategy leads to higher organ preservation rates and should become first line treatment for early rectal cancer.

This objective can be divided into two main questions:

  1. Determine the optimal radiation schedule to achieve the highest rate of organ preservation
  2. Determine the optimal radiation schedule to achieve the best quality of life after organ preservation
03

Conditions studied

  • Adenocarcinoma of the Rectum

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the rectum
  • MRI-defined ≤T3b (with ≤5mm of mesorectal invasion) rectal tumour or endorectal ultrasound-defined ≤uT3b rectal cancer (optional: in centres where high quality endorectal ultrasound (ERUS) is available or patient unable to tolerate MRI)
  • MDT determines that all of the following treatment options are reasonable and feasible:

    --TME surgery, (b) CRT (c) SCRT d) TEM.

  • (ECOG) performance status 0-1
  • For patients choosing organ preservation only:

    • If female and of , must:

      • Have a negative pregnancy test within 7 days prior to study entry
      • Agree to use adequate, medically approved, precautions from trial entry until 6 months after the end of study treatment
    • If non-sterilised male male with a partner of childbearing potential, must:
    • Agree to use adequate, medically approved, contraceptive precautions from trial entry until 6 months after the end of study treatment
  • Patient able and willing to provide written for the study

Exclusion criteria

Exclusion Criteria:

  • Concomitant or previous within 3 years prior to trial entry, except those that in the opinion of the MDT are unlikely to relapse within 3 years or lead to death within 5 years
  • Unequivocal evidence of disease (includes resectable metastases)

    -- Patients with equivocal radiological lesions (e.g. retroperitoneal, liver, lung) that are not classified as M1 are eligible if agreed by MDT

  • MRI node positive (≥N1, defined by protocol guidelines)

    -- Patients with equivocal radiological findings that are either classified as NX or N0 are eligible

  • MRI extramural vascular invasion (mriEMVI) positive (defined by protocol guidelines)
  • MRI defined mucinous tumour
  • Mesorectal fascia threatened (≤1 mm on MRI or ERUS)
  • Maximum tumour diameter > 40mm (either measured from everted edges on sagittal MRI or on ERUS)
  • Tumour position anterior, above the peritoneal reflection on MRI or EUS
  • No residual luminal tumour following endoscopic resection
  • to radiotherapy including previous pelvic radiotherapy
  • Uncontrolled cardiorespiratory comorbidity (includes patients with inadequately controlled angina or myocardial infarction or arrhythmia within 6 months prior to trial entry)
  • Known complete dihydropyrimidine dehydrogenase (DPYD) deficiency
  • Known Gilbert's disease (hyperbilirubinaemia)
  • Taking coumarin-derivative anticoagulants (e.g. warfarin) that cannot be discontinued at least 7 days prior to starting treatment or substituted by low molecular weight heparin
  • Taking phenytoin or sorivudine or its chemically related anologues, such as brivudine, within 4 weeks of trial entry (see Section 8.3.5 for further details)
  • Taking metronidazole at study entry
  • Pregnant or lactating women
  • History of severe and unexpected reactions to fluoropyrimidine therapy
  • Age \<16 years (UK), \<18 years (other countries)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Active comparator
    Standard TME surgery

    Radical total mesorectal excision

    Procedure: Standard TME surgery

  • Experimental
    Long course concurrent chemoradiation

    Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.

    Drug: Long course concurrent chemoradiation with capecitabine and radiotherapy

  • Experimental
    Short course radiotherapy

    A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.

    Radiation: Short course radiotherapy

Interventions

  • ProcedureStandard TME surgery

    Total mesorectal excision

  • DrugLong course concurrent chemoradiation with capecitabine and radiotherapy

    Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.

    Also known as: Xeloda is the brand name for capecitabine

  • RadiationShort course radiotherapy

    A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.

06

What researchers measure

Primary outcomes

  1. Phase II (Feasibility study) Primary Outcome: Recruitment Rate

    Measured at 12 and 24 months. Target recruitment rates are ≥4 and ≥6 patients randomised per month at 12 and 24 months respectively for total accrual of 120 international cases. Each individual country will attempt to exceed the minimum recruitment required to sustain phase III (UK 75, the Netherlands 75, Denmark 30). If recruitment is on target in year two then consideration will be given to an early application for transition to phase III with a funding application and a formal protocol amendment.

    Time frame: 24 Months

  2. Phase III Primary Outcome: Organ Preservation

    The primary endpoint of the STAR-TREC phase III study is the proportion of patients with successful organ preservation at 30 months from the start day of (chemo)radiotherapy treatment. This endpoint will be assessed for patients who prefer organ preservation and is defined as an in-situ rectum (includes patients subject to transanal local resection), no defunctioning stoma and an absence of active loco-regional cancer failure. The expected incidence of this outcome is approximately 60%.

    Time frame: 30 Months from start day of (chemo)radiotherapy treatment.

Secondary outcomes

  1. Phase II (Feasibility study): Core Endpoint - Funding

    Incidence of procurement of funding by one STAR-TREC international partner

    Time frame: 12 Months

  2. Phase II (Feasibility study): Core Endpoint - International Recruitment

    Incidence of opening of STAR-TREC by one international partner

    Time frame: 12 Months

  3. Phase II (Feasibility study): Core Endpoint - Efficacy

    Efficacy of organ preserving treatment arm on completion of phase II study: Is the organ saving rate more than 50% of patients with early stage rectal cancer at 12 months (following randomisation) achieved in the experimental arms? \[Name of Measurement: Rate of organ saving \>50% at 12 months; Unit of Measurement: no record of radical surgery at 12 months\]

    Time frame: 12 Months

  4. Phase II: Safety- Accuracy of MRI in predicting STAR-TREC eligibility

    MRI \- Accuracy of MRI in predicting STAR-TREC eligibility (We will report the accuracy of MRI based patient selection according to each national standard, compared to the reference standard of post-operative histological staging. STAR-TREC will help develop international consensus in MRI reporting of mesorectal lymph node involvement by rectal cancer)

    Time frame: 24 Months

  5. Phase II: Safety - 30 day Mortality

    \- Mortality

    Time frame: 30 days

  6. Phase II: Safety - 6 month Mortality

    \- Mortality

    Time frame: 6 Months

  7. Phase II: Safety - Surgical Morbidity

    \- Surgical morbidity

    Time frame: 36 Months

  8. Phase II: Safety - Tumour Recurrence/ Regrowth within Bowel Wall

    \- Rate of tumour recurrence or regrowth within the bowel wall (experimental arm)

    Time frame: 36 Months

  9. Phase II: Safety - Tumour Recurrence within Mesorectum

    \- Rate of tumour recurrence within the mesorectum (experimental arm)

    Time frame: 36 Months

  10. Phase II: Safety - Distant Metastasis

    \- Rate of distant metastases

    Time frame: 36 Months

  11. Phase II: Safety - Pelvic Failure

    \- Pelvic failure rate: expressed as a sum of the following (i) unresectable pelvic tumour, (ii) cases requiring beyond TME surgery or (iii) tumour recurrence or regrowth ≤1mm from the circumferential surgical margin after TME surgery.

    Time frame: 36 Months

  12. Phase II: Safety - Bowel

    Bowel dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 36 Months

  13. Phase II: Safety - Bladder

    Bladder dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 36 Months

  14. Phase II: Safety - Sexual dysfunction

    Sexual dysfunction measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 36 Months

  15. Phase II: Efficacy - Stoma

    Additional outcome measures pertinent to the phase III study examining the efficacy of organ saving versus standard surgery will also be collected: \- Proportion of patients with/ without a stoma at 30 days and one year

    Time frame: 24 Months

  16. Phase II: Efficacy - Tumour Down-staging

    \- Histopathological assessment of tumour down-staging following radiotherapy according to depth of tumour invasion and the incidence of other high-risk features in comparison to non-irradiated (control) group

    Time frame: 4.5 Months

  17. Phase II: Efficacy - Active Monitoring

    \- Proportion of patients identified by clinical and MRI assessment as suitable for active monitoring

    Time frame: 4.5 Months

  18. Phase II: Efficacy - Conversion Rate

    \- Conversion rates from organ saving to radical surgery

    Time frame: 36 Months

  19. Phase II: Efficacy - Disease Survival

    \- Disease free survival

    Time frame: 36 Months

  20. Phase II: Efficacy - Health-related Quality of Life score

    Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 3 months

  21. Phase II: Efficacy - Health-related Quality of Life score

    Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 12 Months

  22. Phase II: Efficacy - Health-related Quality of Life score

    Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 24 Months

  23. Phase II: Efficacy - Health-related Quality of Life score

    Quality of life measured by EORTC QLQ CR29 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ColoRectal cancer (CR) with 29 items\] \& C30 \[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core with 30 items\], LARS score \[The Low Anterior Resection Syndrome score\], and ICIQ-MLUTS/ICIQ-FLUTS \[International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Module\]. Multiple measurements and scores will be aggregated to arrive at one reported value. Scores at different time points after randomisation will be compared to baseline scores.

    Time frame: 36 Months

  24. Phase II: Efficacy - Overall Survival

    \- Overall survival

    Time frame: 36 Months

  25. Phase III: For the randomised comparison between organ-preserving strategies

    Clinician-reported acute treatment related toxicity up to 30 days following completion of (chemo)radiotherapy

    Time frame: 30 days from start day of (chemo)radiotherapy treatment.

  26. Phase III: Complete Response *For the randomised comparison between organ-preserving strategies

    Proportion of patients with Complete Response to (chemo)radiation therapy

    Time frame: 30 months

  27. Phase III: For the randomised comparison between organ-preserving strategies - Local Excision

    Proportion of patients undergoing transanal local excision

    Time frame: 20 weeks

  28. Phase III: For the randomised comparison between organ-preserving strategies - Organ Loss

    Time to event of organ loss assessed for patients who prefer organ preservation

    Time frame: Defined as the length of time from the start date of trial treatment until TME surgery

  29. Phase III: For the randomised comparison between organ-preserving strategies - Non-Regrowth

    Non-regrowth pelvic tumour control to 36 months; defined as the length of time from the start date of trial treatment until death (any cause) or development of unequivocal pelvic recurrence but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery

    Time frame: 36 months

  30. Phase III: For the randomised comparison between organ-preserving strategies - Metastasis Free Survival

    Metastasis free survival to 36 months; defined as the length of time from the start date of trial treatment until death (any cause) or detection of distant metastasis

    Time frame: 36 months

  31. Phase III: For the randomised comparison between organ-preserving strategies - Non-regrowth Disease Free Survival

    Non-regrowth -disease free survival to 36 months; defined as the length of time from the start of trial treatment until death (any cause), detection of local pelvic recurrence or distant metastasis but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery

    Time frame: 36 months

  32. Phase III: For the randomised comparison between organ-preserving strategies - Overall Survival

    Overall survival to 60 months defined as the length of time from the start date of trial treatment until death (any cause)

    Time frame: 60 months

  33. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Toxicity

    Clinician-reported acute treatment related toxicity up to 30 days following completion of (chemo)radiotherapy or date of initial surgery

    Time frame: 30 days

  34. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Non-regrowth Pelvic Tumour Control

    Non-regrowth pelvic tumour control to 36 months; defined as the length of time from the start date of (chemo)radiotherapy or date of initial surgery until death (any cause) or development of unequivocal pelvic recurrence but not including patients who preferred organ preservation and developed local regrowth which was resected with clear margins using standard TME surgery

    Time frame: 36 months

  35. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Metastasis Free Survival

    Metastasis-free survival to 36 months; defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause) or detection of distant metastasis

    Time frame: 36 months

  36. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Disease-free Survival

    Disease-free survival to 36 months; defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause), detection of local pelvic recurrence or distant metastasis but not including patients who developed local regrowth which was resected with clear margins using standard TME surgery

    Time frame: 36 months

  37. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Overall Survival

    Overall survival to 60 months defined as the length of time from the start date of trial treatment or date of initial surgery until death (any cause))

    Time frame: 60 months

  38. Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret

    Decision regret at 24 months measured using the validated Decision regret scale questionnaire. The Decision Regret Scale is a 5-item Likert-type measure written to assess regret or remorse following a medical decision that takes less than 5 minutes to complete. High scores suggest high regret over a health care decision. Scores may be transformed to a scale of 0 (no regret) to 100 (high regret).

    Time frame: 24 months

07

Study locations

5 sites
08

References and documents

Publications

  • Motamedi MAK, Mak NT, Brown CJ, Raval MJ, Karimuddin AA, Giustini D, Phang PT. Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy. Cochrane Database Syst Rev. 2023 Jun 13;6(6):CD002198. doi: 10.1002/14651858.CD002198.pub3. PubMed 37310167 ↗
  • Appelt AL, Kerkhof EM, Nyvang L, Harderwijk EC, Abbott NL, Teo M, Peters FP, Kronborg CJS, Spindler KG, Sebag-Montefiore D, Marijnen CAM; STAR-TREC collaborative group. Robust dose planning objectives for mesorectal radiotherapy of early stage rectal cancer - A multicentre dose planning study. Tech Innov Patient Support Radiat Oncol. 2019 Oct 15;11:14-21. doi: 10.1016/j.tipsro.2019.09.001. eCollection 2019 Sep. PubMed 32095545 ↗
  • van den Ende RPJ, Peters FP, Harderwijk E, Rutten H, Bouwmans L, Berbee M, Canters RAM, Stoian G, Compagner K, Rozema T, de Smet M, Intven MPW, Tijssen RHN, Theuws J, van Haaren P, van Triest B, Eekhout D, Marijnen CAM, van der Heide UA, Kerkhof EM. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiat Oncol. 2020 Feb 18;15(1):41. doi: 10.1186/s13014-020-01487-6. PubMed 32070386 ↗
  • Rombouts AJM, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach S, Bhangu A, Garm Spindler KL, Gray R, Handley K, Kaur M, Kerkhof E, Kronborg CJ, Magill L, Marijnen CAM, Nagtegaal ID, Nyvang L, Peters FP, Pfeiffer P, Punt C, Quirke P, Sebag-Montefiore D, Teo M, West N, de Wilt JHW; for STAR-TREC Collaborative Group. Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. BMJ Open. 2017 Dec 28;7(12):e019474. doi: 10.1136/bmjopen-2017-019474. PubMed 29288190 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2017 (actual). Primary completion is estimated for Aug 2027, 122 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Oct 26, 2016
StartActual
Jun 14, 2017
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02945566
Responsible party
Sponsor
First posted
Oct 26, 2016
Start date
Jun 14, 2017
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Simon Bach, MD
principal investigator · University Hospitals Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion